BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24120718)

  • 1. No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.
    de Kam PJ; El Galta R; Kruithof AC; Fennema H; van Lierop MJ; Mihara K; Burggraaf J; Moerland M; Peeters P; Troyer MD
    Int J Clin Pharmacol Ther; 2013 Dec; 51(12):976-85. PubMed ID: 24120718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
    De Kam PJ; Kruithof AC; van Lierop MJ; Moerland M; Dennie J; Troyer MD; Langdon RB; Gutstein DE; Burggraaf J; El Galta R
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):631-41. PubMed ID: 24800921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.
    De Kam PJ; Grobara P; Prohn M; Höppener F; Kluft C; Burggraaf J; Langdon RB; Peeters P
    Int J Clin Pharmacol Ther; 2014 Mar; 52(3):227-36. PubMed ID: 24447651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction potential and tolerability of the coadministration of cilostazol and aspirin.
    Mallikaarjun S; Forbes WP; Bramer SL
    Clin Pharmacokinet; 1999; 37 Suppl 2():87-93. PubMed ID: 10702891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
    Dallob A; Luo WL; Luk JM; Ratcliffe L; Johnson-Levonas AO; Schwartz JI; Dishy V; Kraft WK; De Hoon JN; Van Hecken A; De Lepeleire I; Radziszewski W; Wagner JA; Lai E
    Platelets; 2011; 22(7):495-503. PubMed ID: 21526889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A PK-PD model-based assessment of sugammadex effects on coagulation parameters.
    Bosch R; van Lierop MJ; de Kam PJ; Kruithof AC; Burggraaf J; de Greef R; Visser SA; Johnson-Levonas AO; Kleijn HJ
    Eur J Pharm Sci; 2016 Mar; 84():9-17. PubMed ID: 26747019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?
    Wolf HR
    Drugs R D; 2006; 7(3):163-72. PubMed ID: 16752942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients.
    Rahe-Meyer N; Fennema H; Schulman S; Klimscha W; Przemeck M; Blobner M; Wulf H; Speek M; McCrary Sisk C; Williams-Herman D; Woo T; Szegedi A
    Anesthesiology; 2014 Nov; 121(5):969-77. PubMed ID: 25208233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo- controlled study on the anti-haemostatic effects of Curcuma longa, Angelica sinensis and Panax ginseng.
    Fung FY; Wong WH; Ang SK; Koh HL; Kun MC; Lee LH; Li X; Ng HJ; Tan CW; Zhao Y; Linn YC
    Phytomedicine; 2017 Aug; 32():88-96. PubMed ID: 28732813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study.
    Adamopoulos AB; Sakizlis GN; Nasothimiou EG; Anastasopoulou I; Anastasakou E; Kotsi P; Karafoulidou A; Stergiou GS
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):163-8. PubMed ID: 19568178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin at very ultra low dosage in healthy volunteers: effects on bleeding time, platelet aggregation and coagulation.
    Doutremepuich C; de Sèze O; Le Roy D; Lalanne MC; Anne MC
    Haemostasis; 1990; 20(2):99-105. PubMed ID: 2347518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
    Cleanthis M; Bhattacharya V; Smout J; Ashour H; Stansby G
    Eur J Vasc Endovasc Surg; 2009 May; 37(5):604-10. PubMed ID: 19297212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levetiracetam and bleeding disorders.
    Boon P; Hulhoven R; Offner F
    Acta Neurol Belg; 2007 Dec; 107(4):97-102. PubMed ID: 18416281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients.
    Zisman E; Erport A; Kohanovsky E; Ballagulah M; Cassel A; Quitt M; Pizov R
    Eur J Anaesthesiol; 2010 Jul; 27(7):617-23. PubMed ID: 20035230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of aspirin induced changes in bleeding time, platelet aggregation, and Sonoclot coagulation analysis in humans.
    Samra SK; Harrison RL; Bee DE; Valero V
    Ann Clin Lab Sci; 1991; 21(5):315-27. PubMed ID: 1952780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test.
    Kim JS; Lee KS; Kim YI; Tamai Y; Nakahata R; Takami H
    J Clin Neurosci; 2004 Aug; 11(6):600-2. PubMed ID: 15261228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Aspirin Supplementation on Hemostatic Responses in Firefighters Aged 40 to 60 Years.
    Smith DL; Horn GP; Woods J; Ploutz-Snyder R; Fernhall B
    Am J Cardiol; 2016 Jul; 118(2):275-80. PubMed ID: 27241836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.